PEPG PepGen Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1835597 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY21.6%
TTM EPS YoY72.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-55.1%
ROA-46.1%
ROIC (approx.)-121.4%
Asset turnover—
Leverage & solvency
Liabilities / assets19.3%
Debt / equity0.00x
Current ratio8.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $14.48M | $12.52M | $13.00M | $13.85M | $13.42M | $18.39M | $25.38M | $18.96M |
| SG&A expense | $5.91M | $6.42M | $5.94M | $5.85M | $5.23M | $5.54M | $5.94M | $5.38M |
| Operating income | -$20.38M | -$18.94M | -$18.94M | -$19.70M | -$18.65M | -$23.93M | -$31.32M | -$24.34M |
| Pretax income | -$19.38M | -$17.80M | -$17.75M | -$18.29M | -$18.03M | -$23.09M | -$30.20M | -$22.86M |
| Income tax | $13,000 | $16,000 | $15,000 | $48,865 | $0 | $0 | $0 | -$617,000 |
| Net income | -$19.39M | -$17.81M | -$17.76M | -$18.34M | -$18.03M | -$23.09M | -$30.20M | -$22.24M |
| EBITDA | -$20.18M | -$18.64M | -$18.64M | -$19.41M | -$18.35M | -$23.63M | -$30.92M | -$23.95M |
| EPS (basic) | -0.28 | -0.26 | -0.26 | — | -0.52 | -0.70 | -0.92 | — |
| EPS (diluted) | -0.28 | -0.26 | -0.26 | — | -0.52 | -0.70 | -0.92 | — |
| Weighted avg. shares (diluted) | 69.26M | 69.20M | 69.09M | — | 34.36M | 32.75M | 32.67M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $21.96M | $22.76M | $42.15M | $60.51M | $142.78M | $35.07M | $43.63M | $49.42M |
| Short-term investments | $82.85M | $94.47M | $90.15M | $87.94M | $20.89M | $39.58M | $54.15M | $70.77M |
| Current assets | $107.57M | $120.33M | $134.27M | $150.96M | $166.21M | $77.49M | $101.05M | $123.76M |
| PP&E, net | $1.10M | $1.34M | $1.56M | $1.90M | $2.22M | $2.49M | $3.51M | $3.72M |
| Total assets | $127.78M | $141.40M | $156.29M | $173.91M | $190.06M | $102.24M | $127.39M | $150.88M |
| Current liabilities | $12.36M | $9.01M | $8.96M | $12.65M | $12.64M | $16.36M | $20.43M | $16.70M |
| Total liabilities | $24.71M | $21.86M | $22.32M | $26.46M | $26.92M | $31.08M | $35.59M | $32.26M |
| Shareholders' equity | $103.07M | $119.53M | $133.98M | $147.44M | $163.14M | $71.16M | $91.81M | $118.62M |
| Shares outstanding | — | — | — | 68.87M | — | — | — | 32.62M |
| Cash flow statement | ||||||||
| Operating cash flow | -$13.18M | -$15.81M | -$18.43M | -$15.85M | -$19.26M | -$23.60M | -$22.93M | -$19.48M |
| Capital expenditure | $0 | $30,000 | $0 | -$1,000 | $97,000 | $43,000 | $125,000 | $228,000 |
| Free cash flow | -$13.18M | -$15.84M | -$18.43M | -$15.84M | -$19.36M | -$23.64M | -$23.05M | -$19.70M |
| Investing cash flow | $12.46M | -$3.52M | -$1.46M | -$66.24M | $18.90M | $14.96M | $17.15M | $26.50M |
| Financing cash flow | -$86,000 | -$65,000 | $1.52M | -$171,000 | $108.05M | $98,000 | $0 | $128,000 |
| Depreciation & amortization | $200,000 | $300,000 | $300,000 | $300,000 | $300,000 | $300,000 | $400,000 | $400,000 |
| Stock-based compensation | $2.96M | $3.31M | $2.85M | $2.44M | $2.38M | $2.36M | $3.43M | $3.35M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.